Related Articles
Soluble urokinase‑type plasminogen activator receptor and urokinase‑type plasminogen activator receptor contribute to chemoresistance in leukemia
suPAR, a soluble form of urokinase plasminogen activator receptor, inhibits human prostate cancer cell growth and invasion
New ELISA for quantitation of human urokinase receptor (CD87) in cancer.
Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: An EORTC Receptor and Biomarker Group collaboration
Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients.